Wolverine Trading’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-14,900
Closed -$1.29M 4785
2024
Q4
$1.29M Buy
14,900
+3,800
+34% +$348K ﹤0.01% 2404
2024
Q3
$1.03M Buy
11,100
+3,700
+50% +$368K ﹤0.01% 2322
2024
Q2
$798K Buy
+7,400
New +$741K ﹤0.01% 2404
2023
Q4
Sell
-9,600
Closed -$482K 4509
2023
Q3
$482K Buy
+9,600
New +$513K ﹤0.01% 2810
2023
Q2
Sell
-6,600
Closed -$292K 4276
2023
Q1
$292K Hold
6,600
﹤0.01% 3041
2022
Q4
$289K Buy
+6,600
New +$317K ﹤0.01% 2792

Other funds holding BPMC

Wolverine Trading's BPMC Position: Q1 2025 in Review

Wolverine Trading sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 7,811 shares — an estimated $678K sold.

Wolverine Trading first reported a position in BPMC in Q1 2023 and held it in 5 quarters. The position peaked at $1.03M in Q2 2024. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • Wolverine Trading reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
  • Wolverine Trading sold 7,811 Blueprint Medicines shares in Q1 2025, an estimated $678K.
  • Wolverine Trading first reported a position in Blueprint Medicines in Q1 2023 and held it in 5 quarters.
  • Wolverine Trading's Blueprint Medicines position peaked at $1.03M in Q2 2024.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on Wolverine Trading's 13F filing for Q1 2025, filed 15 May 2025.